Drug intelligence / Profile preview

KN5507

Development stage: Preclinical
Lead developer: Rui Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KN5507 is a chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy under development by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.). The therapy is part of a pipeline of "First-in-Class" CAR-NK candidates. KN5507 is designed to leverage the innate cytotoxic capabilities of NK cells, enhanced by a CAR to specifically target and eliminate cells expressing a particular antigen. As of early 2024, the specific molecular target and the primary disease indication for KN5507 remain undisclosed, and the program is in the early preclinical research phase.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on KN5507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN5507.

Explore the full profile